BioSpace News Archive

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced the U.S. launch of OviTex IHR Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio.

UNITY Biotechnology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Walden Biosciences, Inc. announced the results from the Company’s Phase 1+ clinical study of WAL0921 in healthy subjects.

Ocular Therapeutix, Inc. announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer, and that Antony Mattessich is stepping down as President and CEO, effective immediately.

TFF Pharmaceuticals, Inc. announced additional positive data from the ongoing Phase 2 study which is evaluating Tacrolimus Inhalation Powder for the prevention of organ rejection in lung transplant recipients.

Marinus Pharmaceuticals, Inc. announced that an independent Data Monitoring Committee has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous ganaxolone for the treatment of refractory status epilepticus following an interim analysis.

Immix Biopharma, Inc. today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore May 7-11, 2024.

Oxurion NV, a biopharmaceutical company headquartered in Leuven, has published its annual report for the financial year 2023.

The global pharmacogenomics market size was reached at USD 15 billion in 2022 and is forecasted to be worth over USD 35.67 billion by 2032 with a CAGR of 9.1% from 2023 to 2032.